Norgine has announced that Swissmedic has approved the registration of IFINWIL (eflornithine) as a monotherapy for treating ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic.

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Swissmedic approves Novartis’ Coartem Baby to treat malaria in newborns and young infants: Basel Thursday, July 10, 2025, 11:00 Hrs [IST] Novartis announced Coartem (artemether- ...

IFINWIL®: now approved in Switzerland1Nine out of 10 cases of neuroblastoma occur in children under the age of five2The average survival rate of children with HRNB is only 50%2UXBRIDGE, England ...

Switzerland’s health regulator Swissmedic granted marketing authorisation on Tuesday for Novartis Riamet Baby, also known as ...

Swissmedic approves Norgine’s Ifinwil for children diagnosed with high-risk neuroblastoma: Uxbridge, UK Thursday, July 10, 2025, 17:00 Hrs [IST] Norgine, a leading European spec ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants.

The treatment was approved under Swissmedic’s Marketing Authorization for Global Health Products (MAGHP), which helps speed access to medicines for diseases affecting sub-Saharan Africa, The ...

IFINWIL®: now approved in Switzerland1Nine out of 10 cases of neuroblastoma occur in children under the age of five2The average survival rate of children with HRNB is only 50%2UXBRIDGE, England ...